Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence
The impact of the COVID-19 pandemic has been dramatic worldwide, with China, Italy, and now US at its epicenter. Researchers and clinicians are studying and testing different approaches in the attempt to prevent the infection and minimize its severity. Major efforts are focused on optimizing mechani...
Main Authors: | Filippo Drago, Lucia Gozzo, Li Li, Andrea Stella, Benilde Cosmi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.579886/full |
Similar Items
-
Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial
by: Seyed Hamid Borsi, et al.
Published: (2021-07-01) -
Comparison of Intravenous Enoxaparin with Subcutaneous Enoxaparin in Preventing Venous Thromboembolism in Patients Admitted to Intensive Care Unit
by: Masoum Khoshfetrat, et al.
Published: (2020-05-01) -
Once-daily versus twice-daily enoxaparin for the initial treatment of acute deep venous thrombosis: a case–control study
by: Mohamad T Yusuf, et al.
Published: (2019-01-01) -
Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment
by: Natal'ya Mikhaylovna Vorob'eva, et al.
Published: (2009-09-01) -
Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial
by: Ahmad Mirdamadi, et al.
Published: (2014-11-01)